Immunovant, Inc. (IMVT)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Loses money on what it sells.
- Revenue
- $7.1M
- Net income
- -$538.2M
- Net margin
- -7585.9%
Little or no net debt.
- Total debt
- $0
- Cash
- $797.8M
- Debt / equity
- 0.00
Comfortably covers what is due within a year.
- Current assets
- $851.2M
- Current liabilities
- $117.1M
- Current ratio
- 7.27
Consumes cash and must keep raising it.
- Operating cash flow
- -$414.3M
- Free cash flow
- -$414.3M
- FCF margin
- -5839.5%
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 205.5M
- Share growth (1y)
- 20.3%
- Cash runway
- 23 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IMVT Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 7.09 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 101.00 K | 105.00 K | 0.00 | 0.00 |
| Gross Profit | 7.09 M | 0.00 | -101.00 K | -105.00 K | 0.00 | 0.00 |
| SG&A Expense | 17.69 M | 17.27 M | 15.44 M | 17.51 M | 26.02 M | 20.17 M |
| R&D Expense | 142.63 M | 142.29 M | 98.92 M | 114.25 M | 101.20 M | 93.65 M |
| Operating Expenses | 160.32 M | 159.55 M | 114.36 M | 131.76 M | 127.22 M | 113.83 M |
| Operating Income | -153.23 M | -159.55 M | -114.36 M | -131.76 M | -127.22 M | -113.83 M |
| Pretax Income | -153.22 M | -150.70 M | -109.08 M | -125.91 M | -119.70 M | -105.87 M |
| Tax Provision | 0.00 | -2.84 M | 1.55 M | 594.00 K | 913.00 K | 583.00 K |
| Net Income | -153.22 M | -147.86 M | -110.64 M | -126.50 M | -120.61 M | -106.45 M |
| EPS (Basic) | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 |
| EPS (Diluted) | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 |
| Shares Outstanding | 205.55 M | 203.71 M | 181.51 M | 173.64 M | 170.87 M | 151.57 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.